Cancer Morbidity in Rheumatoid Arthritis Patients Treated with Proresid^R or Parenteral Gold

References

• Fries JF. Epidemiology of cancer in rheumatoid arthritis: methodologic pitfalls. Am J Med 1985; 78: 124, Suppl 1A
   Web of Science ®Google Scholar
• Castor C W, Bull FE. Review of United States data on neoplasms in rheumatoid arthritis. Am J Med 1985; 78: 33–8, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Prior P. Cancer and rheumatoid arthritis: Epidemiologic considerations. Am J Med 1985; 78: 15–21, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Owen DS, Jr., Waller M, Toone E. Rheumatoid disease and malignancy. Arthritis Rheum 1967; 10: 302–3
   Google Scholar
• Monson R R, Hall AP. Mortality among arthritics. J Chronic Dis 1976; 29: 45947
   Google Scholar
• Isomäki H A, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691–6
   PubMedGoogle Scholar
• Allebeck P. Increased mortality in rheumatoid arthritis. The use of a medical information system for assessment of death risks. Scand J Rheumatol 1982; 11: 81–6
   PubMed Web of Science ®Google Scholar
• Hazleman B L, de Silva M. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982; 41: 12–7, Suppl
   PubMed Web of Science ®Google Scholar
• Baltus J AM, Boersma J W, Hartman A P, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983; 42: 368–73
   PubMed Web of Science ®Google Scholar
• Kirsner A B, Farber S J, Sheon R P, Finkel RI. The incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis. Ann Rheum Dis 1982; 41: 32–3, Suppl
   PubMed Web of Science ®Google Scholar
• Vandenbroucke J P, Hazevoet H M, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984; 11: 158–61
   PubMed Web of Science ®Google Scholar
• Prior P., Symmons DPM, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 128–31
   PubMed Web of Science ®Google Scholar
• Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44–9, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Katusic S, Beard C M, Kurland L T, Weis J W, Bergstralh E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 1985; 78: 50–5, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Fries J F, Bloch D, Spitz P, Mitchell DM. Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 1985; 78: 56–9, Suppl 1A
   PubMed Web of Science ®Google Scholar
• Laakso M, Mutru O, Isomaki H, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1986; 13: 522–6
   PubMed Web of Science ®Google Scholar
• Baker G L, Kahl L E, Zee B C, Stolzer B L, Agarwal A K, Medsger TA. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am J Med 1987; 83: 1–9
   PubMed Web of Science ®Google Scholar
• Silman A J, Petrie J, Hazleman B, Evans S JW. Lymphoproliferative cancer and other malignancy in patients with rheumtoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988–92
   PubMed Web of Science ®Google Scholar
• Matteson E L, Hickey A R, Maguire L, Tilson H H, Urowitz MB. Occurence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991; 18: 809–14
   PubMed Web of Science ®Google Scholar
• Gridley G, McLaughlin J K, Ekbom A, Klareskog L, Adami H-O, Hacker D G, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11
   PubMed Web of Science ®Google Scholar
• Tennis P, Andrews E, Bombardier C, Wang Y, Strand L, West R, et al. Record linkage to conduct an epidemiologic study on the Association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epidemiol 1993; 46: 685–95
   PubMed Web of Science ®Google Scholar
• Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 1993; 29A: 259–63
   PubMed Web of Science ®Google Scholar
• Stähelin H, Cerletti A. Experimentelle Ergebnisse mit den Po-dophyllum-Cytostatica SP-1 und SP-G. Schweiz Med Wo-chenschr 1964; 94: 1490–502
   PubMedGoogle Scholar
• Chlud K, Prohaska E, Zeitlhofer J, Ch Pfaller, Friza B. Immunosuppressive Behandlung der progressiv-chronischen Polyarthritis. Erfahrungen mit einem Antimitotikurn aus der Podophyllinreihe (Proresid). Munch Med Wochenschr 1968; 110: 88–97
   PubMedGoogle Scholar
• Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med 1985; 78: 3943, Suppl 1A
   Web of Science ®Google Scholar
• Berglund K. Postal enkat avseende Proresid (Postal questionnaire regarding Proresid). (In Swedish). Stencil. Lund University 1984
   Google Scholar
• Weitoft T, Lysholm J. Side effects of Proresid in the treatment of chronic arthritis. Scand J Rheumatol 1988; 17: 63–6
   PubMed Web of Science ®Google Scholar
• Bendix G, Bjelle A. Proresid therapy in rheumatoid arthritis. A comparison with injectable gold using life-table analysis. Scand J Rheumatol 1993; 22: 77–82
   PubMed Web of Science ®Google Scholar
• Bendix G, Bjelle A. Outcome of parenteral gold therapy in RA patients: A comparison between two periods using life-table analysis. Br J Rheumatol 1991; 30: 407–12
   PubMedGoogle Scholar
• Branehög I, Holmberg E, Persson G. Cancerstatistik för Västra sjukvårdsregionen 1981–1990. (Cancer statistics Western region of health care in Sweden 1981–1990). Göteborg; Onkologiskt centrum i Vätra sjukvårdsregionen 1993
   Google Scholar
• Bradley JW. Distribution-free statistical tests. Prentice-Hall, London 1968; 68–86
   Google Scholar
• Odén A, Wedel H. Arguments for Fisher's permutation test. Ann Statist 1975; 3: 518–20
   Web of Science ®Google Scholar
• Mantel N. Chi-square test with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58: 690–700
   Web of Science ®Google Scholar
• Lehmann EL. Testing statistical hypotheses2nd ed. Wiley, New York 1986; 231–5
   Google Scholar
• Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet 1993; 342: 819–20
   PubMed Web of Science ®Google Scholar
• Tozman E CS, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol 1987; 2: 177–89
   PubMedGoogle Scholar
• Mitchell D M, Spitz P W, Young D Y, Bloch D A, McShane D J, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706–14
   PubMed Web of Science ®Google Scholar
• Lehtinen K, Isomäki H. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991; 18: 524–9
   PubMed Web of Science ®Google Scholar
• Mattsson B. Cancer registration in Sweden. Studies of completeness and validity of incidence and mortality registers. Thesis, Karolinska institutet, Stockholm 1984
   Google Scholar
• Symmons D PM. Neoplasia in rheumatoid arthritis. J Rheumatol 1988; 15: 1319–22
   PubMed Web of Science ®Google Scholar
• Talal N. Sjögren's syndrome and connective tissue diseases asSociated with other immunologic disorders. Arthritis and allied conditions, D J McCarthy, W J Koopman. Lea & Febiger, Philadelphia 1993; 1343–56
   Google Scholar
• Goldstein BD. Lessons on the second cancers resulting from cancer chemotherapy. Biological reactive intermediates IV. Molecular and cellular effects and their impact on human health, C M Witmer, R R Snyder, D J Jollow, G F Kalf, J J Kocsis, I G Sipes. Plenum press, New York 1990; 619–25
   Google Scholar